AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
carglumic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3068 | 1188-38-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
carglumic acid could be helpful in lowering plasma ammonia levels over 400 micromol/L more rapidly
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 21 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 61 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAPK7,STK33,TEK,TGFBR1,ZAP70 | 13 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 18, 2010 | FDA | ORPHAN EUROPE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Off label use | 81.02 | 78.20 | 43 | 148 | 638292 | 41982852 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ammonia increased | 110.99 | 63.32 | 19 | 263 | 8231 | 110580786 |
| Off label use | 97.61 | 63.32 | 54 | 228 | 1500131 | 109088886 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AA05 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Amino acids and derivatives |
| FDA MoA | N0000184143 | Carbamoyl Phosphate Synthetase 1 Activators |
| FDA EPC | N0000184144 | Carbamoyl Phosphate Synthetase 1 Activator |
| CHEBI has role | CHEBI:71031 | orphan drug |
| CHEBI has role | CHEBI:71033 | carbamylphosphate synthetase I activator |
Related Drugs by ATC class:
A16AA Amino acids and derivatives 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hyperammonemia associated with N-acetylglutamate synthase deficiency | indication | ||
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.57 | acidic |
| pKa2 | 5.14 | acidic |
| pKa3 | 12.49 | acidic |
| pKa4 | 13.51 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 200MG | CARBAGLU | RECORDATI RARE | N022562 | March 18, 2010 | RX | TABLET, FOR SUSPENSION | ORAL | Jan. 22, 2028 | IN PEDIATRIC AND ADULT PATIENTS AS ADJUNCTIVE THERAPY TO STANDARD OF CARE FOR THE TREATMENT OF ACUTE HYPERAMMONEMIA DUE TO PROPIONIC ACIDEMIA (PA) OR METHYLMALONIC ACIDEMIA (MMA) |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Carbamoyl-phosphate synthase [ammonia], mitochondrial | Enzyme | POSITIVE ALLOSTERIC MODULATOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4030904 | VUID |
| N0000182969 | NUI |
| D07130 | KEGG_DRUG |
| 4030904 | VANDF |
| C1318649 | UMLSCUI |
| CHEBI:71028 | CHEBI |
| CHEMBL1201780 | ChEMBL_ID |
| DB06775 | DRUGBANK_ID |
| 121396 | PUBCHEM_CID |
| C528449 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7458 | IUPHAR_LIGAND_ID |
| 8008 | INN_ID |
| 5L0HB4V1EW | UNII |
| 401713 | RXNORM |
| 20611 | MMSL |
| 302324 | MMSL |
| 72491 | MMSL |
| d05656 | MMSL |
| 004390 | NDDF |
| 408045002 | SNOMEDCT_US |
| 412295009 | SNOMEDCT_US |
| 5L0HB4V1EW | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Carglumic acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35573-459 | TABLET, FOR SUSPENSION | 200 mg | ORAL | ANDA | 21 sections |
| Carbaglu | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52276-312 | TABLET, FOR SUSPENSION | 200 mg | ORAL | NDA | 25 sections |
| Carglumic acid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68475-006 | TABLET, FOR SUSPENSION | 200 mg | ORAL | ANDA | 21 sections |
| Carglumic Acid | Human Prescription Drug Label | 1 | 71863-114 | TABLET, FOR SUSPENSION | 200 mg | ORAL | ANDA | 24 sections |